You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 12, 2024

CLINICAL TRIALS PROFILE FOR LOTEPREDNOL ETABONATE; TOBRAMYCIN


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Loteprednol Etabonate; Tobramycin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00420628 ↗ Pediatric Zylet Safety and Efficacy Study Completed Bausch & Lomb Incorporated Phase 4 2006-11-01 A multicenter study to evaluate the safety and efficacy of Zylet compared to vehicle in children aged 0-6 for the management of lid inflammation (chalazion/hordeolum)
NCT00447577 ↗ Zylet vs TobraDex in Blepharokeratoconjunctivitis Completed Bausch & Lomb Incorporated Phase 4 2007-01-01 The objective of this study is to evaluate the safety and efficacy of Zylet vs. Tobradex in the treatment of ocular inflammation associated with blepharokeratoconjunctivitis
NCT00834171 ↗ A Retrospective Evaluation of the Intraocular Pressure Spikes With Loteprednol and Loteprednol/Tobramycin Completed Allergan 2009-01-01 Patient charts will be reviewed to evaluate the incidence of intraocular pressure spikes while on Loteprednol etabonate ophthalmic suspension 0.5%, Loteprednol etabonate (0.5%) and tobramycin (0.3%)
NCT00905762 ↗ Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After Topical Instillation Completed Bausch & Lomb Incorporated Phase 1 2009-03-01 The purpose of this study is to assess the concentration of besifloxacin compared to gatifloxacin and moxifloxacin in human conjunctival tissue, following a single drop of the drug instilled topically into the study eye. Conjunctival biopsies will be performed at specified time points, followed by the use of loteprednol etabonate/tobramycin ophthalmic suspension four times a day for 5 days.
NCT01028027 ↗ Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis Completed Bausch & Lomb Incorporated Phase 3 2009-10-01 This study is to evaluate the safety and efficacy of loteprednol etabonate [LE] and tobramycin ophthalmic suspension versus tobramycin and dexamethasone ophthalmic suspension in the treatment of ocular inflammation associated with blepharokeratoconjunctivitis (BKC).
NCT03464435 ↗ A Novel Combined Therapy for Refractory Vernal Keratoconjunctivitis Completed Zhongshan Ophthalmic Center, Sun Yat-sen University Phase 4 2016-11-01 To evaluate the efficacy and safety of 0.1% tacrolimus combined with loteprednol etabonate 0.5%/tobramycin 0.3% (LE/T) in vernal keratoconjunctivitis (VKC) patients resistant to conventional treatment. This prospective 6-mouth period study aims to include 20 severe VKC patients who were not responding to conventional treatments. All the patients will be treated with 0.1% tacrolimus suspension two times daily, LE/T eye drops four times daily for 1 month. Additionally, 0.1% olopatadine two times daily and preservative-free artificial tears four times daily will be used. After the first month, LE/T will be stopped, with other treatments continued for the last 5 months. Visual acuity and intraocular pressure (IOP) will be measured at enrollment and 1, 2, 3 and 6 months after treatment. Besides, 6 subjective symptoms and 6 clinical signs will be graded at each visit based on a 4-point scale. The primary endpoints are the change in symptoms and objective signs. Treatment failure will be recorded if extra corticosteroids were required.
NCT05353101 ↗ Cyclosporine 0.05% Eye Drops for Vernal Keratoconjunctivitis Trial Completed Second Affiliated Hospital of Nanchang University Phase 1 2020-07-01 To observe and compare the clinical efficacy of cyclosporine 0.05% eye drops with Loteprednol Etabonate 0.5% and Tobramycin Eye Drops 0.3% in the treatment of Vernal Keratoconjunctivitis in developing regions of China.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Loteprednol Etabonate; Tobramycin

Condition Name

Condition Name for Loteprednol Etabonate; Tobramycin
Intervention Trials
Vernal Keratoconjunctivitis 2
Blepharitis 1
Blepharokeratoconjunctivitis 1
Chalazion 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Loteprednol Etabonate; Tobramycin
Intervention Trials
Conjunctivitis, Allergic 2
Keratoconjunctivitis 2
Chalazion 1
Keratitis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Loteprednol Etabonate; Tobramycin

Trials by Country

Trials by Country for Loteprednol Etabonate; Tobramycin
Location Trials
United States 4
China 1
Singapore 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Loteprednol Etabonate; Tobramycin
Location Trials
North Carolina 1
Pennsylvania 1
New York 1
Virginia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Loteprednol Etabonate; Tobramycin

Clinical Trial Phase

Clinical Trial Phase for Loteprednol Etabonate; Tobramycin
Clinical Trial Phase Trials
Phase 4 3
Phase 3 1
Phase 1 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Loteprednol Etabonate; Tobramycin
Clinical Trial Phase Trials
Completed 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Loteprednol Etabonate; Tobramycin

Sponsor Name

Sponsor Name for Loteprednol Etabonate; Tobramycin
Sponsor Trials
Bausch & Lomb Incorporated 4
Allergan 1
Zhongshan Ophthalmic Center, Sun Yat-sen University 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Loteprednol Etabonate; Tobramycin
Sponsor Trials
Industry 5
Other 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.